Concepedia

Publication | Closed Access

Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy

DOI

78

Citations

33

References

2011

Year

Aziz Zaanan, Jean–François Fléjou, Jean‐François Emile, Guetz Gaëtan Des, Peggy Cuillière-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier,
Clinical Cancer Research

Abstract

MMR status is an independent prognostic biomarker for DFS in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy.

References

YearCitations

Page 1